Abstract：
BACKGROUND: Pulmonary Mucormycosis (PM) is a relatively uncommon fungal disease, usually manifested in immunocompromised patients. It has an aggressive course, along with dilemmas in diagnosis and treatment. In view of the surge of Mucormycosis patients in COVID 19 pandemic, clinicians need to consider PM in suspected cases, and act in an expedited manner to avoid misdiagnosis and initiate prompt treatment.
METHODS: In this case series, we present four cases of PM with varied presentation, clinical course and discuss management strategies.
CONCLUSIONS: A strong suspicion of PM based on epidemiological and clinical findings should be considered, to ensure appropriate and timely treatment. It should be accompanied by judicious use of corticosteroids and aggressive control of comorbid conditions to decrease preventable morbidity and mortality.
METHODS: In this case series, we present four cases of PM with varied presentation, clinical course and discuss management strategies.
CONCLUSIONS: A strong suspicion of PM based on epidemiological and clinical findings should be considered, to ensure appropriate and timely treatment. It should be accompanied by judicious use of corticosteroids and aggressive control of comorbid conditions to decrease preventable morbidity and mortality.
摘要：
背景：肺毛霉菌病（PM）是一种相对罕见的真菌病，通常表现在免疫功能低下的患者。它有一个侵略性的过程，以及诊断和治疗的困境。鉴于COVID19大流行的毛霉菌病患者激增，临床医生需要在疑似病例中考虑PM，并迅速采取行动，以避免误诊并立即开始治疗。
方法：在本例系列中，我们介绍了四个不同的PM案例，临床课程和讨论管理策略。
结论：应考虑基于流行病学和临床发现对PM的强烈怀疑，确保适当和及时的治疗。应伴随着合理使用皮质类固醇和积极控制共病，以降低可预防的发病率和死亡率。
方法：在本例系列中，我们介绍了四个不同的PM案例，临床课程和讨论管理策略。
结论：应考虑基于流行病学和临床发现对PM的强烈怀疑，确保适当和及时的治疗。应伴随着合理使用皮质类固醇和积极控制共病，以降低可预防的发病率和死亡率。
